Who makes IgM rich Immunoglobin?

IgM rich Immunoglobin is developed by Sir Takhtasinhji General Hospital.

What development phase is IgM rich Immunoglobin in?

IgM rich Immunoglobin is FDA-approved (marketed).

What are the side effects of IgM rich Immunoglobin?

Common side effects include Infusion reactions (fever, chills, flushing), Headache, Myalgia, Thrombotic events, Renal dysfunction.

Last reviewed 2026-04-22 · How we verify

IgM rich Immunoglobin

Sir Takhtasinhji General Hospital · FDA-approved active Small molecule

IgM-rich immunoglobulin provides passive immune support by supplying IgM antibodies to enhance complement activation and opsonization of pathogens.

IgM-rich immunoglobulin provides passive immune support by supplying IgM antibodies to enhance complement activation and opsonization of pathogens. Used for Immunoglobulin M deficiency, Sepsis and severe infections in immunocompromised patients, Post-operative infection prophylaxis.

At a glance

Generic name	IgM rich Immunoglobin
Also known as	Pentaglobin®
Sponsor	Sir Takhtasinhji General Hospital
Drug class	Immunoglobulin replacement therapy
Target	IgM antibodies; complement system (C1q)
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Mechanism of action

IgM is the first antibody produced during primary immune responses and is highly effective at activating the classical complement pathway. IgM-rich immunoglobulin preparations deliver exogenous IgM to boost innate immune defenses, particularly useful in immunocompromised patients or those with severe infections. This enhances pathogen neutralization and clearance through complement-mediated and antibody-dependent cellular mechanisms.

Approved indications

Immunoglobulin M deficiency
Sepsis and severe infections in immunocompromised patients
Post-operative infection prophylaxis

Common side effects

Infusion reactions (fever, chills, flushing)
Headache
Myalgia
Thrombotic events
Renal dysfunction

Key clinical trials

Efficacy of IgM Rich Immunoglobulin With Antibiotics for Bacterial Sepsis in Very Low Birth Weight Preterm Neonates (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IgM rich Immunoglobin CI brief — competitive landscape report
IgM rich Immunoglobin updates RSS · CI watch RSS
Sir Takhtasinhji General Hospital portfolio CI